ArticleBMC gastroenterology2025
Laparoscopic retroperitoneal necrosectomy in patients with necrotizing pancreatitis: addressing the limitations of traditional treatment options.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robot-assisted pancreatic necrosectomy for infected pancreatic necrosis secondary to severe acute pancreatitis: a single-center retrospective cohort study.Journal of robotic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLaparoscopic retroperitoneal necrosectomy (LRN) is a novel minimally invasive approach for treating infected necrotizing pancreatitis. Our study aims to evaluate the safety and effectiveness of LRN for pancreatic necrosis at a single center.
methodsThis retrospective study analyzed 120 patients who had laparoscopic retroperitoneal necrosectomy (LRN) for necrotizing pancreatitis at Sir Run Run Shaw Hospital from November 2017 to May 2023, with a six-month follow-up. Patients included had no prior surgeries. We evaluated the incidence of postoperative complications and mortality rates. Furthermore, subgroup analyses were performed to assess mortality and complications, utilizing univariate and multivariate regression analyses to identify associated risk factors.
resultsAmong the 120 patients, complications classified as Clavien-Dindo grade ≥ III occurred in 34.2%, and 8.3% experienced surgery-related mortality. In the multivariate regression analysis of complications classified as Clavien-Dindo grade ≥ III, length of stay (LOS) in the ICU (OR = 1.026;95% confidence interval [CI], 1.005 to 1.047; P = 0.015), and the presence of extrapancreatic infections (OR = 3.656;95% confidence interval [CI], 1.443to 9.261; P = 0.006) were identified as risk factors. A total of 77 patients with severe acute pancreatitis (according to the modified Atlanta classification) were included in the study. After 48 h of treatment, the SOFA score significantly decreased (5.92 ± 4.56 vs. 4.06 ± 3.44; P < 0.01), and the CT severity index (CTSI) also significantly decreased at one week post-surgery (7.57 ± 2.29 vs. 6.23 ± 2.28; P < 0.01). CRP levels (144.34 ± 77.45 vs. 87.94 ± 67.63; P < 0.01) and WBC count (10.97 ± 6.84 vs. 9.95 ± 6.79; P = 0.048) significantly decreased within one week after surgery. Among the 23 patients with preoperative hemodynamic instability, 13 required only a single surgery, while 4 required conversion to open surgery. At 48 h post-surgery, the SOFA score significantly decreased (8.74 ± 5.71 vs. 6.17 ± 4.94; P = 0.021), and the CTSI at one week was also considerably lower (8.26 ± 2.03 vs. 6.78 ± 2.04; P < 0.01).
conclusionLRN allows over 70% of patients to avoid multiple surgeries while achieving excellent therapeutic outcomes. Furthermore, it is particularly effective for critically ill patients with hemodynamic instability, offering a distinct advantage over alternative treatments. Thus, LRN represents a promising therapeutic approach deserving of broader adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.